Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | LIPE | Q05469 | 2/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30127016 | 0.90 | USP30 (0.45) | GPR119PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL30125744 | 0.83 | PIK3CD (0.39) | GPR119PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL30125930 | 0.79 | EGFR (0.49) | USP30 | |
| SCHEMBL30126933 | 0.77 | PIK3CD (0.44) | PIK3CDPIK3CAPIK3CBPIK3CGUSP30 | |
| SCHEMBL2411817 | 0.76 | HRH3 (0.55) | GPR119USP30LIPE | |
| SCHEMBL2411815 | 0.76 | HRH3 (0.55) | GPR119USP30LIPE | |
| SCHEMBL2884981 | 0.76 | GPR119 (0.52) | GPR119USP30LIPEJAK1 | |
| SCHEMBL649953 | 0.76 | GPR119 (0.47) | GPR119USP30LIPE | |
| SCHEMBL653024 | 0.76 | GPR119 (0.47) | GPR119USP30LIPE | |
| SCHEMBL650888 | 0.76 | GPR119 (0.47) | GPR119USP30LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022266458-A1 | 6-HETEROCYCLOALKYL-QUINAZOLINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |